Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development and FDA-approval of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Moreover, these vital healthcare providers need education on disease pathophysiology, burden, and the impact this illness imparts on the whole patient.
- CMHC
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
$0.00
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), and despite a higher HF symptom burden, they are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future.
- CMHC
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
$0.00
Atrial fibrillation (AF) remains underdiagnosed, particularly in African American patients with a high burden of AF risk factors, such as those with cardiometabolic comorbidities. Additionally, stroke prevention in these patients is suboptimal, with suboptimal application of evidence-based therapies and guidelines, including the suboptimal use of direct oral anticoagulants (DOACs).
- LivDerm
- TME
- 1.00 AAPA Category I CME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Pediatric patients with skin of color (SOC) face unique challenges in managing AD, including issues with disease associated sequelae. In fact, these patients are more likely to suffer from more severe AD cases. It has also been observed that patients with darker pigmented skin are more likely to develop hypo or hyperpigmentation at the affected sites of disease, and these effects often remain long after the symptoms have gone.
- CMHC
- 1.25 ABIM MOC and AMA PRA Category 1 Credit™
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 CDE
- 1.25 Participation
$0.00
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that clinicians face in reducing the burden of anemia in patients with CKD.
- LivDerm
- TME
- 1.00 AAPA Category I CME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Psoriasis is an immune-mediated disease that currently affects more than 8 million Americans and 125 million people worldwide according to the World Psoriasis Day consortium. Symptoms of this disease are characterized by inflammation, commonly presenting as raised plaques and scales on the skin resulting from an overactive immune system.
- LivDerm
- TME
- 2.00 AAPA Category I CME
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC
- 2.00 Participation
$0.00
The ever-increasing impact of dermatologic conditions continues to be a major challenge for dermatologists and other health care providers in the United States (US). Dermatology practitioners diagnose and treat more than 3000 diseases across the age spectrum. Therefore, clinicians are challenged to remain current in their knowledge and competence in the diagnosis and management of cutaneous disease.
- CMHC
- 1.25 ABIM MOC and AMA PRA Category 1 Credit™
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 CDE
- 1.25 Participation
$0.00
Lowering LDL-C effectively and safely is crucial to prevent and lower the risk of adverse cardiovascular events, however, LDL-C goal achievement remains suboptimal, including in high-risk and very high-risk patients. The landscape of LDL-C lowering therapy has significantly evolved, with new consensus statements, newer agents, as well as important evidence that may help address some of the current gaps. Additionally, there is residual risk beyond LDL-C, including elevated triglyceride levels and elevated Lp(a).
- CMHC
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), Additionally, the impact of commonly-used medications with high sodium content contributes to this burden. As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including in patients with sleep disorders, as well as practical strategies to minimize the impact of elevated sodium.
- LivDerm
- TME
- 2.00 ACPE Pharmacy
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC
- 2.00 Participation
$0.00
Hidradenitis suppurativa has significant impacts on patients’ quality of life, however, it remains underdiagnosed, misdiagnosed, or incorrectly treated. Until recently, there was a scarcity of evidence about long-term management strategies and no evidence-based consensus guidelines. The updated North American guidelines, as well as the growing armamentarium of agents in advanced clinical development, provide additional guidance for optimizing diagnosis and treatment of HS patients. However, questions still remain about how to best individualize therapy and work as a partner with patients